International urology and nephrology · 2026
Micro-ultrasound guided versus multiparametric MRI-guided prostate biopsy: a systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moynagh Niamh, Bruinsma Josh, Mac Curtain Benjamin M, Calpin Gavin G, Elfaki Mohamed, Nikolenko Rostyslav, Deshwal Avinash, Clausen Nicholas, Benour Ali, Qian Wanyang, Temperley Hugo C, Lawlor Peter, Keane John, Cozman Claudiu, Yap Lee Chien, Daly Padraig J
Аннотация
PURPOSE: To investigate patients with suspected prostate cancer, multiparametric MRI (mpMRI) has been the standard imaging modality employed. However, mpMRI is costly and not universally available. Microultrasound (mUS), a novel 29-MHz modality, offers high-resolution, real-time prostate imaging and may guide biopsy with comparable diagnostic accuracy. This systematic review and meta-analysis compares mUS-guided and mpMRI-guided prostate biopsy for the detection of prostate cancer (PCa).
METHODS: A systematic search was conducted up to April 2025, in accordance with the PRISMA guidelines (PROSPERO ID CRD420251033768). Comparative studies reporting PCa detection between mUS and mpMRI were included.
RESULTS: Twelve studies comprising 4318 patients (3475 mUS; 3615 mpMRI) were included. There was no significant difference between modalities in the detection of clinically significant prostate cancer (csPCa), both overall (RR 0.97; 95%CI 0.90-1.05) and with targeted biopsy (RR 1.05; 95%CI 0.97-1.14). Overall cancer detection was also comparable (RR 1.00; 95%CI 0.87-1.15), as was Grade Group 1 prostate cancer detection, whether assessed across all biopsies (RR 1.00; 95%CI 0.72-1.39) or with targeted biopsy alone (RR 0.90; 95%CI 0.64-1.27). Weighted pooled values showed mUS had a sensitivity of 93.2%, specificity of 23.3%, positive predictive value (PPV) of 46.4%, and negative predictive value (NPV) of 81.2%, compared with mpMRI's sensitivity of 87.5%, specificity of 25.7%, PPV of 44.6%, and NPV of 73.7%.
CONCLUSION: mUS-guided biopsy demonstrates diagnostic performance comparable to mpMRI-guided biopsy for PCa detection and represents a promising alternative or adjunct to mpMRI in prostate cancer diagnostic pathways.
METHODS: A systematic search was conducted up to April 2025, in accordance with the PRISMA guidelines (PROSPERO ID CRD420251033768). Comparative studies reporting PCa detection between mUS and mpMRI were included.
RESULTS: Twelve studies comprising 4318 patients (3475 mUS; 3615 mpMRI) were included. There was no significant difference between modalities in the detection of clinically significant prostate cancer (csPCa), both overall (RR 0.97; 95%CI 0.90-1.05) and with targeted biopsy (RR 1.05; 95%CI 0.97-1.14). Overall cancer detection was also comparable (RR 1.00; 95%CI 0.87-1.15), as was Grade Group 1 prostate cancer detection, whether assessed across all biopsies (RR 1.00; 95%CI 0.72-1.39) or with targeted biopsy alone (RR 0.90; 95%CI 0.64-1.27). Weighted pooled values showed mUS had a sensitivity of 93.2%, specificity of 23.3%, positive predictive value (PPV) of 46.4%, and negative predictive value (NPV) of 81.2%, compared with mpMRI's sensitivity of 87.5%, specificity of 25.7%, PPV of 44.6%, and NPV of 73.7%.
CONCLUSION: mUS-guided biopsy demonstrates diagnostic performance comparable to mpMRI-guided biopsy for PCa detection and represents a promising alternative or adjunct to mpMRI in prostate cancer diagnostic pathways.